Lin-Juan Xu, Jing Cai, Wei-Hong Dong, Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Bang-Xing Huang, Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Author contributions: Xu LJ and Dong WH performed conceptualization; Xu LJ, Cai J and Dong WH participated in investigation; Xu LJ and Huang BX designed data curation; Xu LJ prepared original draft; Xu LJ, Cai J, Huang BX and Dong WH contributed to writing-review and editing; all authors have read and agreed to the published version of the manuscript.
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: The authors have nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Wei-Hong Dong, PhD, Chief Physician, Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. rubydwh@126.com
Received: May 5, 2022 Peer-review started: May 5, 2022 First decision: May 31, 2022 Revised: June 4, 2022 Accepted: August 5, 2022 Article in press: August 5, 2022 Published online: September 16, 2022 Processing time: 119 Days and 17.2 Hours
Core Tip
Core Tip: Because of the extreme rarity of adult primary cervical rhabdomyosarcomas, their treatment remains challenging. Accurate diagnosis is critical for a good prognosis since the treatment of cervical rhabdomyosarcoma differs from that of other cervical tumors, particularly in radicality of surgery and chemotherapy regimens. Our experience suggests that neoadjuvant vincristine, dactinomycin, and cyclophosphamide chemotherapy followed by radical surgery and adjuvant chemotherapy might be reasonable therapeutic option for bulky cervical rhabdomyosarcoma in adults without fertility desire. Since large-scale studies on such rare conditions are rather impossible, further case reports and systematic reviews could help optimize the treatment of primary, bulky cervical rhabdomyosarcoma in adults.
